Spero Therapeutics, Inc.
SP001, a third-generation anti-CD40L monoclonal antibody therapeutic
- Sector
- Biotech
- Headquarters
- MA
- Founded
- 2013
- Latest Form D
- $9M, Nov 2022
- Total capital
- $159M
- Federal grants
- $1.4M
- 2 awards · 2017–2018
- Rank in peer group#206 of 326
- Private capital raised
- $92.2M
- 3 Form D · last Nov 2022
- 47 months since last filing
- Federal contracts
- $65.6M
- 3 awards · Health and Human S
- Rank in Biotech#12 of 4373
- Granted patents
- 7
- 26 pending · first 2021
- Rank in peer group#25 of 326
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 3rd filing$9M
- Private capital raisedForm D · SEC · 2nd filing$40M
- Federal contractHealth and Human S · To Advance Clinical And Non-clinical Development Of An Antibiotic Candidate.$10.5M
- Federal contractHealth and Human S · Igf::ot::igf$49.2M
- Federal grantHealth and Human S · Phase II · A Novel Gyrase Inhibitor for the Treatment of Drug-susceptible and Multidrug-resistant Mycobacterium tuberculosis Infections$425K
- Private capital raisedForm D · SEC · 1st filing$43.2M
- Federal grantHealth and Human S · Phase II · A Novel Gyrase Inhibitor for the Treatment of Drug-susceptible and Multidrug-resistant Mycobacterium tuberculosis Infections$990K
Show 1 earlier federal award
- Federal contractHealth and Human S · Igf::ot::igf - "development Of A Second Generation Polymyxin For Therapy Of Mdr Gram-negative Infections"$5.9M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
21months
from Spero Therapeutics, Inc.’s first federal award to its first private round.
- First federal award · Jun 2015
- Health and Human S · $5.9M
- First Form D · Mar 2017
- $43.2M · 1st Form D
- Awards before first raise
- 2 awards
An association in public records, not a cause or a prediction.
Standing among 326 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Granted patents#25 · top 8%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Ankit MahadeviaExecutive Officer, DirectorNamed in SEC Form D filings
- Casper BreumDirectorNamed in SEC Form D filings
- Cristina E. LarkinExecutive OfficerNamed in SEC Form D filings
- Cynthia SmithDirectorNamed in SEC Form D filings
- David E. MelnickExecutive OfficerNamed in SEC Form D filings
- Frank E. ThomasDirectorNamed in SEC Form D filings
Show all 21 people
- Frank E. ThomasDirectorNamed in SEC Form D filings
- Jean-Francois FormelaDirectorNamed in SEC Form D filings
- John C. Pottage, Jr.DirectorNamed in SEC Form D filings
- John C. Pottage, Jr.DirectorNamed in SEC Form D filings
- Kamal HamedExecutive OfficerNamed in SEC Form D filings
- Kathleen TregoningDirectorNamed in SEC Form D filings
- Milind DeshpandeDirectorNamed in SEC Form D filings
- Patrick C. VinkDirectorNamed in SEC Form D filings
- Reza HalseDirectorNamed in SEC Form D filings
- Satyavrat ShuklaExecutive OfficerNamed in SEC Form D filings
- Scott JacksonDirectorNamed in SEC Form D filings
- Stephen GarbaczExecutive OfficerNamed in SEC Form D filings
- Tamara JosephExecutive OfficerNamed in SEC Form D filings
- Timothy E. KeutzerExecutive OfficerNamed in SEC Form D filings
- Vikas GoyalDirectorNamed in SEC Form D filings
What it has protected
USPTO · 7 granted of 33- PendingHigh Dosage Tebipenem Pivoxil Tablet FormulationUSPTOApplication 19554575
- PendingTebipenem Pivoxil Crystalline Forms, Compositions Including The Same, Methods Of Manufacture, And Methods Of UseUSPTOApplication 19554577
- PendingTebipenem Pivoxil Immediate And Modified Release Oral Dosage FormsUSPTOApplication 19554579
Show all 33 patent records
- High Dosage Tebipenem Pivoxil Tablet FormulationJul 9, 2026 · Application 19554575Pending
- Tebipenem Pivoxil Crystalline Forms, Compositions Including The Same, Methods Of Manufacture, And Methods Of UseJul 9, 2026 · Application 19554577Pending
- Tebipenem Pivoxil Immediate And Modified Release Oral Dosage FormsJul 9, 2026 · Application 19554579Pending
- Aryl Substituted Polymyxin DerivativesApr 16, 2026 · Application 19415229Pending
- Aryl Substituted Polymyxin DerivativesJan 20, 2026 · US 12,528,837Granted
- Novel Tebipenem Pivoxil Immediate And Modified Release Oral Dosage FormsFeb 18, 2025 · US 12,226,403Granted
- High Dosage Tebipenem Pivoxil Tablet FormulationFeb 13, 2025 · Application 18665330Pending
- Tebipenem Pivoxil Crystalline Forms, Compositions Including The Same, Methods Of Manufacture, And Methods Of UseFeb 13, 2025 · Application 18823147Pending
- Tebipenem Pivoxil Immediate And Modified Release Oral Dosage FormsJan 9, 2025 · Application 18888372Pending
- Human Efficacious Dose And Dosage Schedule Of SPR720Nov 7, 2024 · Application 18646893Pending
- Tebipenem Pivoxil Crystalline Forms, Compositions Including The Same, Methods Of Manufacture, And Methods Of UseSep 24, 2024 · US 12,098,155Granted
- High Dosage Tebipenem Pivoxil Tablet FormulationJul 30, 2024 · US 12,048,691Granted
- Polymyxin Derivatives And Their Use In Combination Therapy Together With Different AntibioticsOct 12, 2023 · Application 18126270Pending
- Tebipenem Pivoxil Crystalline Forms, Compositions Including The Same, Methods Of Manufacture, And Methods Of UseAug 8, 2023 · US 11,718,621Granted
- Polymyxin CompoundsOct 4, 2022 · US 11,459,357Granted
- Polymyxin Derivatives And Their Use In Combination Therapy Together With Different AntibioticsJul 22, 2021 · Application 17157393Pending
- Tebipenem Pivoxil Crystalline Forms, Compositions Including The Same, Methods Of Manufacture, And Methods Of UseJan 12, 2021 · US 10,889,587Granted
- CompoundsApplication 63110765Pending
- High Dosage Tebipenem Pivoxil Tablet FormulationApplication PCTUS2021059178Pending
- Tebipenem Pivoxil Crystalline Forms, Compositions Including The Same, Methods Of Manufacture, And Methods Of UseApplication PCTUS2018017067Pending
- Novel Tebipenem Pivoxil Immediate And Modified Release Oral Dosage FormsApplication PCTUS2017066729Pending
- Aryloxyacetylindoles And Analogs As Antibiotic Tolerance InhibitorsApplication PCTUS2016012308Pending
- Human Dosage For SPR720 For Treating Mycobacteria Pulmonary DiseaseApplication 63300145Pending
- Human Efficacious Dose And Dosage Schedule Of SPR720Application PCTUS2022047865Pending
- Carbonyl Linked Bicyclic Heteroaryl N-benzimidazoles And Analogs As Antibiotic Tolerance InhibitorsApplication PCTUS2015049619Pending
- Carbonyl Linked Bicyclic Heteroaryl Antibiotic Tolerance InhibitorsApplication PCTUS2015039911Pending
- Aryloxyacetylindoles And Analogs As Antibiotic Tolerance InhibitorsApplication 62141642Pending
- Aryloxyacetylindoles And Analogs As Antibiotic Tolerance InhibitorsApplication 62100205Pending
- Carbonyl Linked Bicyclic Heteroaryl N-benzimidazoles And Analogs As Antibiotic Tolerance InhibitorsApplication 62049670Pending
- Human Dosage for SPR720 For Treating Mycobacteria Pulmonary DiseaseApplication 63272052Pending
- Carbonyl Linked Bicyclic Heteroaryl Antibiotic Tolerance InhibitorsApplication 62023820Pending
- CompoundsApplication PCTUS2021058182Pending
- High Dosage Tebipenem Pivoxil Tablet FormulationApplication 63112434Pending
Related companies, and why
- VEDANTA BIOSCIENCES, INC.Similar federal contract value in Biotech · $99.1M in contracts
- CONTINUUS Pharmaceuticals, Inc.Similar federal contract value in Biotech · $73.7M in contracts
- GUILD ASSOCIATES INCSimilar federal contract value in Biotech · $69.6M in contracts
- CRESTONE, INC.Similar federal contract value in Biotech · $61.5M in contracts
- Cidara TherapeuticsSimilar federal contract value in Biotech · $58.1M in contracts
- 3D SystemsSimilar federal contract value in Biotech · $52.7M in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .